FDA
-
-
-
-
-
-
-
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
-
-
-
-
-
-
-
Tonix presents fibromyalgia patient data at ISPOR meeting
-
-
-
-
-
-
-
Tonix plans phase 2 study of lyme disease prevention drug by 2027
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington
-
-
-
-
-
-
-
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
-
-
-
-
-
-
-
Tonix gets FDA clearance for major depression study of TNX-102 SL
-
326,143 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

